Controlled trials of a polyvalent pseudomonas vaccine in burns.
A polyvalent pseudomonas vaccine has been tested in controlled clinical trials at two burns units, in Birmingham and New Delhi, in children and adults with burns more than 15% full skin thickness. None of the vaccinated patients in either trial showed blood cultures containing Pseudomonas aeruginosa, and vaccinees showed raised titres of protective antibody and increased phagocytic activity against Ps. aeruginosa. In the New Delhi unit, where death from Ps. aeruginosa infection is common, the mortality in adults was reduced from 40.6% (13/32) in the unvaccinated group to 6.6% (2/30) in the vaccinated group, and in children from 20.8% (5/24) in the unvaccinated group to 4.8% (1/21) in the vaccinated group.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000032:analysis; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D002056:Burns / Q000382:microbiology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004739:England; D006801:Humans; D007194:India; D007223:Infant; D008297:Male; D008875:Middle Aged; D010587:Phagocytosis / Q000187:drug effects; D011552:Pseudomonas Infections / Q000401:mortality / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000276:immunology*
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines